<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        APOLLO Insurance, a Canadian digital insurance provider, has partnered with Dream Unlimited to provide instant digital insurance solutions designed specifically for tenants across Canada.
      </p>
    </li>
    <li>
      <p>
        The partnership enables Dream to offer APOLLO's digital insurance platform to its residents, making it easy and affordable for them to get comprehensive tenant insurance policies.&nbsp;
      </p>
    </li>
    <li>
      <p>
        This partnership supports Dream's goal of sustainable affordability and improves the rental experience for residents. Additionally, property managers will find it easier to track resident insurance compliance through APOLLO's integration with property management software.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20240710397447/en/APOLLO-and-Dream-Partner-to-Offer-Digital-Insurance-to-Residents">
      Press release
    </a>
  </p>
</div>


InsurTech: Personal Lines

PROMINENT_CATEGORY

<div>
 
 <p>APOLLO Insurance, a Canadian digital insurance provider, has partnered with Dream Unlimited to provide quick and user-friendly digital insurance solutions for tenants all over Canada.</p>
 <p>This collaboration allows Dream to provide APOLLO's digital insurance platform to its residents, aiming to make tenant insurance policies both easier and more economical.</p>
 <p>This partnership aligns with Dream's commitment to sustainable affordability and enhancing the tenants' rental experience. Additionally, property managers will benefit from easier tracking of resident insurance adherence due to APOLLO's compatibility with property management software.</p>
 
</div>

APOLLO and Dream partner to offer digital insurance to residents

Old CRMs were complicated, expensive, and limited. Simpler, cheaper CRMs targeting SMEs have arrived.

SME CRM

<div>
 <p>ServiceTitan has introduced three new solutions powered by Artificial Intelligence: Contact Center Pro, Sales Pro, and TI Assist. These new tools leverage the company's proprietary AI system, Titan Intelligence. The solutions aim to assist contractors in managing their operations more efficiently. They promise to streamline processes, predict outcomes, and enhance overall business operations through automation.</p>
</div>

ServiceTitan launches three AI solutions for trades businesses

Empowering Tomorrow's Innovations with Generative AI Infrastructure

Generative AI Infrastructure

INCUMBENTS_PRESENT

<div>
 <p>Amazon has combined its data warehouse service, Amazon Redshift, with Amazon Bedrock, a service for foundation models. This integration is available where both Amazon Bedrock and Amazon Redshift ML are supported, and uses standard Amazon Bedrock pricing. It lets users carry out GenAI tasks with SQL commands and access foundation models like Claude, Llama 2, and Mistral AI.</p>
 <p>The synergy between these services enables customers to conduct language translation, text generation, summarization, classification, and sentiment analysis on Redshift data utilizing SQL, thereby making GenAI more straightforward in data analytics.</p> 
</div>

AWS integrates Amazon Redshift with Amazon Bedrock

Additive manufacturing makes objects by systematically adding material via a CAD program

Additive Manufacturing

<div>
 <p>Ulendo Technologies, a company that specializes in 3D printing software, has partnered with Rev1 Technologies, the exclusive US after-sales support provider for CreatBot, to offer a new software upgrade. This upgrade enhances the performance of industrial 3D printers.</p>
 <p>The partnership will combine the vibration compensation algorithm of Ulendo with the CreatBot F430 3D printer. This collaboration allows for a 5x increase in printing speed, without compromising its quality. Both new and existing F430 printers can avail this upgrade, with an expansion plan for the software to other CreatBot large-size and high-temperature printers, scheduled for later this year.</p>
 <p>Ulendo, a spin-off company from the University of Michigan founded in 2018, is renowned for its advanced software solutions for manufacturing automation, particularly 3D printing. Its flagship product, Ulendo FBS (Filtered B Splines), is a vibration compensation software contributing to higher operation speeds of 3D printers, without affecting the print quality and the need for installing hardware modifications. Ulendo FBS operates by intercepting and modifying GCODE instructions to compensate for vibrations in 3D printers with moving mechanical printheads.</p>  
</div>

Ulendo partners with Rev1 Technologies to launch software upgrade that boosts industrial 3D printer speeds

Technologies bringing about a new reality

Extended Reality

ANALYST_QUICK_TAKE

<div>
 <p>Neural interface tech company, Afference, secured USD 3.5 million in a seed funding round, with investors including Hannah Grey VC, Konvoy, and Samsung Next.</p>
 <p>This investment will fast-track the development of haptic solutions, including the Afference Ring, set to debut at CES 2025.</p>
 
</div> <p><b>Analyst QuickTake:<br>
</b> The round follows Afference raising USD 1.5 million in <a href="https:<br>
//sp-edge.com/updates/22215"> September 2023 </a> , which it used to develop its "Phantom" neural interface platform. Phantom uses electrical signals to create skin sensations interpreted by the brain and connects to spatial computing platforms via Bluetooth, including VR/AR.</p>

Afference raises USD 3.5 million in seed funding to improve haptic solutions

Disrupting the traditional financial system using blockchain

Decentralized Finance (DeFi)

<div>
 <p>Phoenix, a cryptocurrency exchange developed by Ellipsis Labs, has managed to secure a funding of USD 21 million. This funding was led by Haun Ventures and included contributions from other existing investors such as Electric Capital, Anatoly Yakovenko, and Paradigm. With this round, the total funding secured by the company has reached USD 44 million.</p>
 <p>This recent amount of funding will speed up the development of Atlas, a new blockchain specifically designed for verifiable finance. Set to launch as a layer-2 solution on Ethereum, Atlas will connect with the liquidity pools of both Ethereum and Solana. The new solution will provide low-latency transaction processing, consistent Oracle updates, and non-custodial, on-chain price discovery sequencing.</p> 
</div>

Ellipsis Labs raises USD 21 million in funding from Haun Ventures

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>

<p>Absci, an AI-based drug development firm, and Twist Bioscience, a Californian pharmacogenomics organization, will collaborate to create a novel therapeutic for an undisclosed target using GenAI. The partnership will utilize Absci’s GenAI and Twist's DNA platforms to develop a new therapeutic candidate.</p>

<p>The technology anticipated from this collaboration is projected to enhance the process of antibody design, testing, and validation. The goal of these combined efforts is to provide patients with faster, more effective treatment options.</p>

</div> <p><b>Analyst QuickTake:<br>
</b> Absci’s zero-shot GenAI capabilities have been utilized by Big Pharma company AstraZeneca in <a href="https:<br>
//sp-edge.com/updates/24554"> December 2023 </a> as part of a deal worth USD 247 million to leverage Absci’s AI models combined with a high-throughput wet lab setup to&nbsp;discover a potential new cancer treatment candidate for an undisclosed target.</p>

Absci and Twist Bioscience collaborate to design novel therapeutics using GenAI

<div>
 
 <p>Biotechnology company 1910 Genetics, powered by artificial intelligence (AI), has received a funding from investment firm Accenture Ventures. The exact investment amount remains undisclosed. The funds will complement 1910 Genetics' AI drug discovery initiatives.</p>
 <p>The company plans to use the investment to extend its operations and assist in its development endeavours.</p>
 <p>1910 Genetics catalyses small and large molecule drug discovery through its multimodal AI platform, enhanced by laboratory automation. Its exclusive Input-Transform-Output (ITO) platform marries AI with computational data, proxy biological data from wet labs, and ground truth biological data from wet labs, aiming at delivering effective drug candidates across a wide range of therapeutic areas.</p>
 
</div>

1910 Genetic receives investment from Accenture Ventures to support AI drug discovery and development

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

<div>

 <p>Bionano Genomics has concluded a registered direct offering involving the sale and purchase of roughly 9.9 million common shares, together with Series C and D warrants for the purchase of an equivalent number of common shares. Each unit was priced around USD 0.30, bringing in approximately USD 3 million in gross proceeds. If the warrants were to be fully exercised on a cash basis, additional income of around USD 6 million could be generated.</p>
 <p>It is anticipated that these funds will be used for basic corporate requirements such as working capital, research and development costs, repayment or redemption of existing debt, and capital investments.</p>
 
</div>

Bionano Genomics raises USD 3 million in registered direct funding for general corporate needs

<div>
 
 <p>Ataraxis AI, an AI-powered precision medicine company, has raised USD 4 million in a seed funding round. The investment was led by Giant Ventures and Obvious Ventures.</p>
 <p>These funds will be utilized to accelerate Ataraxis AI's research and development efforts. The company aims to develop AI-based diagnostic tests to improve the forecasting of patient outcomes and allow for more accurate treatments.</p>
 <p>The firm is primarily focused on revolutionizing cancer diagnostics and patient outcomes. It has developed Kestrel, an AI model for digital pathology which identifies new features related to patient outcomes. This surpasses human expertise in various disease types. Ataraxis AI's first product, Ataraxis Breast, is an AI-based prognostic and predictive test for breast cancer. It is claimed to be 30% more precise than standard genomic assays.</p>
 
</div>

Ataraxis AI raises USD 4 million in seed funding to develop AI-based diagnostic tests

<div>

<p>Biotechnology company Evommune has obtained a significant USD 115 million in a Series C funding round. This round saw participation from new as well as existing investors, including RA Capital Management and Sectoral Asset Management, which co-led the round, and B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund, RTW Investments, and others. Current investors such as Pivotal bioVenture Partners, EQT Life Sciences, and Verition Fund Management also took part in the funding round.</p>

<p>The resources acquired will accelerate the development of Evommune's key clinical programs, notably EVO756 and EVO301. Scheduled Phase II trials for EVO756, targeted to treat chronic urticaria and atopic dermatitis, as well as a Phase II proof-of-concept study for EVO301 are on the horizon. The company anticipates outcomes from these trials during 2025 and 2026.</p>

<p>Evommune concentrates on the creation of treatments for chronic inflammatory ailments. It employs a human tissue-based assay system for drug discovery, which allows researchers to inspect inflammatory pathways in living skin derived from human donors. The leading candidate of the company, EVO756, is a powerful oral small molecule that aims at the MRGPRX2 receptor located on mast cells and peripheral neurons.</p>

</div>

All Updates

APOLLO and Dream partner to offer digital insurance to residents

ServiceTitan launches three AI solutions for trades businesses

AWS integrates Amazon Redshift with Amazon Bedrock

Ulendo partners with Rev1 Technologies to launch software upgrade that boosts industrial 3D printer speeds

Afference raises USD 3.5 million in seed funding to improve haptic solutions

Ellipsis Labs raises USD 21 million in funding from Haun Ventures

Absci and Twist Bioscience collaborate to design novel therapeutics using GenAI

1910 Genetic receives investment from Accenture Ventures to support AI drug discovery and development

Bionano Genomics raises USD 3 million in registered direct funding for general corporate needs

Ataraxis AI raises USD 4 million in seed funding to develop AI-based diagnostic tests

Evommune raises USD 115 million in Series C funding to advance key clinical programs

InsurTech: Personal Lines

APOLLO and Dream partner to offer digital insurance to residents

Contact us